JPMorgan Chase & Co. Has $1.36 Million Holdings in Clover Health Investments, Corp. (NASDAQ:CLOV)

JPMorgan Chase & Co. boosted its holdings in shares of Clover Health Investments, Corp. (NASDAQ:CLOV - Free Report) by 172.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 432,268 shares of the company's stock after buying an additional 273,348 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.09% of Clover Health Investments worth $1,362,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in CLOV. Steph & Co. boosted its holdings in shares of Clover Health Investments by 33.3% during the fourth quarter. Steph & Co. now owns 20,000 shares of the company's stock worth $63,000 after acquiring an additional 5,000 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Clover Health Investments in the 3rd quarter valued at $105,000. Ballentine Partners LLC acquired a new stake in shares of Clover Health Investments during the fourth quarter worth $131,000. Palacios Wealth Management LLC bought a new stake in shares of Clover Health Investments in the fourth quarter valued at about $131,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Clover Health Investments in the fourth quarter valued at about $135,000. 19.77% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Clover Health Investments

In other news, Director Carladenise Armbrister Edwards sold 200,000 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $3.61, for a total transaction of $722,000.00. Following the completion of the transaction, the director now directly owns 273,227 shares in the company, valued at approximately $986,349.47. This represents a 42.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Karen Soares sold 52,500 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $3.80, for a total value of $199,500.00. Following the sale, the general counsel now owns 1,299,663 shares in the company, valued at $4,938,719.40. This represents a 3.88 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 327,500 shares of company stock valued at $1,197,500. 22.28% of the stock is currently owned by corporate insiders.

Clover Health Investments Stock Down 1.0 %

Shares of NASDAQ:CLOV traded down $0.04 during midday trading on Thursday, hitting $3.37. The stock had a trading volume of 892,462 shares, compared to its average volume of 6,800,342. The company has a market capitalization of $1.72 billion, a P/E ratio of -16.77 and a beta of 1.98. The company's 50-day moving average price is $3.64 and its 200-day moving average price is $3.74. Clover Health Investments, Corp. has a fifty-two week low of $0.63 and a fifty-two week high of $4.87.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group lifted their price objective on shares of Clover Health Investments from $4.20 to $4.50 and gave the stock a "buy" rating in a research note on Monday, March 3rd.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.